Map | A Partnership for Children's Health Search:  Advanced Search
Home General Information Country Support Board Task Forces Resources Media Center
About the Board Last Board Meeting Members Board Reports EC reports Private Access
Printer-friendly format

Quick Reference:

What is GAVI?

GAVI Alliance fact sheets


Board Documents


Press Releases

Immunization Information

Immunization Forum
Latest Issue

GAVI Update



Paris, France, 19-20 July, 2005
Summary Report

>>Back to the 16th GAVI Board Meeting
  • Presentation:  Merceline Dahl-Regis, Investment case review team
    ( PPT - 193K)
  • Bridge Financing Investment Case
    ( PDF - 300K)
  • 4. Bridge financing investment case

    • The feasibility of co-financing will depend upon the willingness and ability of country governments and other donors to contribute to vaccine costs.
    • The process for handling countries in crises, or those unable to meet their co-financing obligations, requires further development.
    • Explicit mechanisms for monitoring the implementation of bridge financing will need to be established, so that operations can be modified as needed.
    • Policies must be developed and applied with manufacturers and markets in mind. For example, some concern was expressed regarding the setting of a so-called “working price” given the risks of creating market constraints and the many variables in calculating such a price. Even so, there was recognition of the need to set a certain parameter for future planning and financial projections.
    • Even though financing more expensive vaccines is proving a significant challenge, the programmatic benefits of combination vaccines are still highly valued by the countries.


    The Board:

      4.1 Endorsed the three main principals of the bridge financing:

        4.1.1 Flatline support (extending 100% support through 2007 – affects 11 countries)

        4.1.2 The concept of a “working” price given the need for a figure for planning and budgeting, with a request to come up with a new name that better reflects its imprecision.

        4.1.3 Co-financing, so that countries make commitments to gradually increase non-GAVI contributions to the vaccine’s costs over the years through 2015.

      4.2 Agreed that the project management structure as proposed needs to be reconsidered to ensure that it strengthens capacity of countries and builds upon existing structures and capacity of partners.

      4.3 Endorsed the proposed budget envelope of $520 million as a provisional total, with the understanding that should assumptions about vaccine price declines not materialize, the costs of bridge financing would increase. The Board will need to be kept regularly informed.

    >>Back to the 16th GAVI Board Meeting

    Go here for presentations

    Go here for documents


    1. Report from the field: Malawi
    2. GAVI/Vaccine Fund in Phase 2—Executive Secretary Report
    3. Investment case development, review and decision-making process
    4. Bridge financing investment case
    5. New vaccines in phase 2
    6. IFFIm-Dependent Investment Cases
    7. Long-term supply and procurement strategy
    8. The International Finance Facility for Immunization
    9. Immunization services support and health system strengthening
    10. Technical support in phase 2
    11. GAVI/VF 2006-07 Work Plan Framework
    12. Yellow fever stockpile evaluation
    star_int   Contact us | Guestbook | Copyrights | Text site